Search Results - Qingbo Liu

  • Showing 1 - 3 results of 3
Refine Results
  1. 1

    Melatonin receptor 1a alleviates sleep fragmentation-aggravated testicular injury in T2DM by suppression of TAB1/TAK1 complex through FGFR1 by Xiaohui Zhang, Xinyu Tang, Ting Gao, Yuanfang Guo, Guangping Lu, Qingbo Liu, Jiahao Li, Jie Wang, Mingrui Liu, Dongmei Zhang, Yufeng Tang, Junlian Gu

    Published 2025-07-01

    A major obstacle in type 2 diabetes mellitus (T2DM) is sleep fragmentation (SF), which negatively affects testicular function. However, the underlying mechanisms remain to be elucidated. In this study, we demonstrate that SF induces testicular damage through a mechanism involving lipid metabolism, s...

    Full description

    Get full text
    Article
  2. 2

    Neuraminidase 1 Exacerbated Glycolytic Dysregulation and Cardiotoxicity by Destabilizing SIRT1 through Interactions with NRF2 and HIF1α by Ting Gao, Yufeng Tang, Tao Zeng, Jie Wang, Xiaohui Zhang, Qingbo Liu, Xun Guan, Xinyu Tang, Guangping Lu, Jiahao Li, Mingrui Liu, Dongmei Zhang, Sixuan Lv, Junlian Gu

    Published 2025-07-01

    Abstract Despite significant therapeutic advances, cumulative DOX‐induced cardiotoxicity (DIC) events remain unacceptably high. Recent evidence has underscored the critical role of impaired glycolytic metabolism in cardiovascular damage. Neuraminidase 1 (NEU1), a member of the neuraminidase family,...

    Full description

    Get full text
    Article
  3. 3

    Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain by Young D. Kwon, Amarendra Pegu, Eun Sung Yang, Baoshan Zhang, Michael F. Bender, Mangaiarkarasi Asokan, Qingbo Liu, Krisha McKee, Bob C. Lin, Tracy Liu, Mark K. Louder, Reda Rawi, Mateo Reveiz, Andrew J. Schaub, Chen-Hsiang Shen, Nicole A. Doria-Rose, Paolo Lusso, John R. Mascola, Peter D. Kwong

    Published 2023-12-01

    The amino-acid composition of the immunoglobulin variable region has been observed to impact antibody pharmacokinetics (PK). Here, we sought to improve the PK of the broad HIV−1-neutralizing VRC01-class antibodies, VRC07-523LS and N6LS, by reducing the net positive charge in their variable domains....

    Full description

    Get full text
    Article